Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)

NCT01327651 is registered in ClinicalTrials.gov with HIV Prevention Trials Network as lead sponsor.

NCT NCT01327651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)
Lead sponsor
HIV Prevention Trials Network
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2014
Enrollment
622 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections